{"product_id":"tirreta-60-mg-self-mix","title":"Noventra Pharma TirReta 60 mg Self-Mix","description":"\u003ch1 data-pm-slice=\"1 1 []\"\u003e\u003cspan\u003eNoventra Pharma TirReta 60 mg — Self-Mix Vial Kit\u003c\/span\u003e\u003c\/h1\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eMetabolic Research | Dual-Compound Formulation | GLP-1, GIP \u0026amp; Glucagon Pathways\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003eProduct Overview\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eNoventra Pharma TirReta 60 mg is a self-mix vial-format product labelled as containing a 60 mg multidose ampule, supplied with a separate 2 ml ampule of bacteriostatic water.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe manufacturer's online listing identifies TirReta as a combination of \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003e30 mg tirzepatide and 30 mg retatrutide\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e. Confirm this composition against the current product label and batch documentation before relying on it.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eTirzepatide acts on GIP and GLP-1 receptors, while retatrutide is an investigational compound that activates GIP, GLP-1 and glucagon receptors. These pathways are being studied for their roles in appetite signalling, glucose regulation, energy balance and body-weight management.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003eResearch Background\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eTirzepatide\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eClinical trials have demonstrated improvements in blood-glucose control in people with type 2 diabetes and significant average body-weight reductions in adults with obesity or overweight in dedicated weight-management studies.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eRetatrutide\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIn a Phase 2 obesity trial, retatrutide produced substantial average body-weight reductions over 48 weeks. Its triple-receptor mechanism remains under investigation, and additional research is needed to establish its safety and efficacy.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eImportant distinction:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e These findings relate to the individual compounds studied in controlled clinical trials. They do not demonstrate that combining the two compounds produces greater benefits, or establish the safety, effectiveness or stability of this particular formulation.\u003c\/span\u003e\u003c\/p\u003e","brand":"Noventra","offers":[{"title":"Default Title","offer_id":51026689491169,"sku":null,"price":1640.0,"currency_code":"ZAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0825\/1935\/9713\/files\/Noventra-Pharma-TirReta-60mg-Multi-Dose-Ampule-Self-Mix-card-768x538.png?v=1793173449","url":"https:\/\/health-tech.co.za\/products\/tirreta-60-mg-self-mix","provider":"Health Tech","version":"1.0","type":"link"}